Northern Trust
OBIO icon

Northern Trust’s Orchestra BioMed OBIO Stock Holding History

Northern Trust’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$503K Buy
118,274
+7,375
+7% +$31.4K ﹤0.01% 3615
2025
Q4 		$460K Buy
110,899
+8,327
+8% +$33.6K ﹤0.01% 3683
2025
Q3 		$254K Buy
102,572
+2,137
+2% +$5.9K ﹤0.01% 3895
2025
Q2 		$269K Sell
100,435
-138,266
-58% -$404K ﹤0.01% 3838
2025
Q1 		$1.02M Buy
238,701
+1,940
+0.8% +$9.64K ﹤0.01% 3267
2024
Q4 		$947K Buy
236,761
+5,725
+2% +$30.8K ﹤0.01% 3420
2024
Q3 		$1.19M Buy
231,036
+87,749
+61% +$573K ﹤0.01% 3281
2024
Q2 		$1.17M Buy
143,287
+3,250
+2% +$18.8K ﹤0.01% 3173
2024
Q1 		$738K Sell
140,037
-2,842
-2% -$19.3K ﹤0.01% 3420
2023
Q4 		$1.3M Sell
142,879
-1,632
-1% -$11.1K ﹤0.01% 3214
2023
Q3 		$1.26M Buy
144,511
+88,804
+159% +$597K ﹤0.01% 3192
2023
Q2 		$390K Buy
55,707
+32,299
+138% +$490K ﹤0.01% 3604
2023
Q1 		$458K Buy
+23,408
New +$271K ﹤0.01% 3509

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust's OBIO Position: Q1 2026 in Review

Northern Trust increased its Orchestra BioMed (OBIO) stake by 6.7% in Q1 2026, buying an estimated $31.4K and bringing the position to 118,274 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #3615.

Northern Trust first reported a position in OBIO in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.3M in Q4 2023. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Northern Trust held 118,274 shares of Orchestra BioMed worth $503K as of Q1 2026.
  • Northern Trust bought 7,375 Orchestra BioMed shares in Q1 2026, an estimated $31.4K.
  • Orchestra BioMed made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3615 holding.
  • Northern Trust first reported a position in Orchestra BioMed in Q1 2023 and has held it in 13 quarters since.
  • Northern Trust's Orchestra BioMed position peaked at $1.3M in Q4 2023.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.